Vincerx Pharma (VINC) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

VINC Vincerx Pharma

Watchlist

0.352
+0.025+7.52%

Close Nov 11 16:00 ET

0.358
+0.006+1.73%

Post 20:02 ET

10.87MMarket Cap-308P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

What Makes Vincerx Pharma (VINC) a New Buy Stock
Yahoo FinanceOct 10 12:00 ET
Vincerx Pharma Is Maintained at Outperform by Leerink Partners
Dow JonesOct 8 11:57 ET · Ratings
Vincerx Pharma Analyst Ratings
BenzingaOct 8 11:45 ET · Ratings
Penny Stock Cancer-Focused Vincerx Pharma Seeks Development Partner For 2 Early-Stage Blood Cancer Candidates
BenzingaOct 8 10:38 ET
Leerink Partners Maintains Vincerx Pharma(VINC.US) With Buy Rating, Cuts Target Price to $2
Moomoo NewsOct 8 10:32 ET · Ratings
Vincerx Stock Tumbles 20% on Corporate Updates
Seeking AlphaOct 8 10:28 ET

Comments

Rivera

Oct 8 10:35

Reload

$Vincerx Pharma (VINC.US)$

Jaguar8

Oct 8 03:41

There you go. But not playing bec I’ll be sleeping 😂

$Vincerx Pharma (VINC.US)$

Rivera

Oct 7 15:50

The way is up up

$Vincerx Pharma (VINC.US)$

Trytosaveabit

Oct 7 15:06

Update

$Vincerx Pharma (VINC.US)$ Reuters· just
Vincerx Reports Positive Initial Clinical Data From Ongoing Vip943 Phase 1 Dose-Escalation Study and Provides Pipeline and Corporate Updates

Jaguar8

Oct 7 15:05

NEWS

$Vincerx Pharma (VINC.US)$
Vincerx Reports Positive Initial Clinical Data from Ongoing VIP943 Phase 1 Dose-Escalation Study and Provides Pipeline and Corporate Updates
VIP943 demonstrates promising safety and tolerability and achieves two complete responses to date in Phase 1 dose-escalation study, reinforcing the program's potential and validating the VersAptx™ Platform technology
Vincerx focusing resources on continued development of VIP943
Expected cash runway into early 2025
Managemen...

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

VINC Vincerx Pharma

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target